Department of Cardiology, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Catheterization Laboratories, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
EuroIntervention. 2023 Apr 24;18(17):1446-1455. doi: 10.4244/EIJ-D-22-00909.
There are limited data regarding the long-term prognosis of percutaneous coronary intervention treatment for left main (LM) ostial stenosis.
The present study sought to investigate the long-term clinical outcomes and risk factors for adverse events in LM ostial lesions following drug-eluting stent implantation (DES) in a large cohort of an LM registry database.
Patients presenting with LM coronary disease from January 2004 to December 2016 at Fuwai Hospital were included. The primary endpoint was target vessel failure (TVF), a composite endpoint of cardiac death, target vessel myocardial infarction and target vessel revascularisation. Cox proportional hazards models were constructed to identify independent predictors.
Among 4,625 LM patients, 627 (13.6%) patients were identified with LM ostial lesions. There were more female patients in the ostial group (31.3%), compared with the shaft (18.1%) and bifurcation groups (19.9%) (p<0.0001). Among patients with DES implantation, 3-year TVF occurred in 44 patients (7.5%) in the ostial group, which is comparable with the other two groups. Myocardial infarction (MI) was significantly lower in the ostial group (2.0%) compared with the bifurcation group (4.2%) (p=0.02), especially for MI events originating in the LM vessel (p=0.02). For patients with ostial LM disease who received percutaneous coronary intervention (PCI) treatment, procedural complications were an independent risk factor for long-term cardiac death or MI, while a more recent PCI proved to be a protective factor.
PCI treatment for ostial LM lesions achieved favourable long-term outcomes, with a similar MI risk compared with the mid-shaft group but a significantly lower risk of MI compared with the distal group.
关于经皮冠状动脉介入治疗左主干(LM)开口狭窄的长期预后数据有限。
本研究旨在通过 LM 注册数据库的大样本,探讨药物洗脱支架(DES)置入后 LM 开口病变的长期临床结果和不良事件的危险因素。
纳入 2004 年 1 月至 2016 年 12 月在阜外医院就诊的 LM 冠状动脉疾病患者。主要终点是靶血管失败(TVF),即心源性死亡、靶血管心肌梗死和靶血管血运重建的复合终点。构建 Cox 比例风险模型来确定独立预测因素。
在 4625 例 LM 患者中,有 627 例(13.6%)患者存在 LM 开口病变。开口组的女性患者(31.3%)多于中段(18.1%)和分叉组(19.9%)(p<0.0001)。DES 置入患者中,开口组 3 年 TVF 发生率为 44 例(7.5%),与另外两组相似。心肌梗死(MI)在开口组(2.0%)显著低于分叉组(4.2%)(p=0.02),尤其是源于 LM 血管的 MI 事件(p=0.02)。对于接受经皮冠状动脉介入治疗(PCI)的开口 LM 病变患者,操作并发症是长期心源性死亡或 MI 的独立危险因素,而近期 PCI 则是保护因素。
对于开口 LM 病变的 PCI 治疗可获得良好的长期结果,与中段组的 MI 风险相似,但与远端组相比,MI 风险显著降低。